<DOC>
	<DOCNO>NCT02053285</DOCNO>
	<brief_summary>Dual-energy CT ( DECT ) provide information blood volume tumor lymph node . As tumor respond treatment , preliminary data suggests blood volume change well . Investigators therefore use DECT test whether use radiation treatment rapidly assess response treatment .</brief_summary>
	<brief_title>Pilot Study Novel Type CT Scan Assess Treatment Response During Chemoradiotherapy Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Patients age great 18 year diagnosis stage III nonsmall cell lung cancer . Planned treatment either definitive chemoradiotherapy preoperative chemoradiotherapy follow surgical resection . PETCT study within 4 week next available DECT study . Patients must measurable primary nodal disease , define least one lesion ( primary lymph node ) great 1 cm . Kidney function sufficient tolerate iodinebased CT contrast . No allergy iodinebased contrast . Ability understand willingness sign inform consent . Participants prior history thoracic radiotherapy . Participants may receive study agent . Inability tolerate CT contrast Pregnant woman exclude study radiotherapy potential teratogenic abortifacient effect . Because unknown potential risk adverse event nurse infant secondary treatment mother radiotherapy , breastfeed discontinue mother treated radiotherapy . These potential risk may also apply agent use study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>